February 22, 2017 / 1:34 PM / 5 months ago

Argos says independent committee suggests stopping carcinoma study

1 Min Read

Feb 22 (Reuters) - Argos Therapeutics Inc said on Wednesday that an independent data monitoring committee has recommended the company to discontinue its late-stage trial for the treatment of metastatic renal cell carcinoma.

The company said the IDMC concluded that the company's combination treatment was unlikely to demonstrate a statistically significant improvement, the primary goal of the study. (Reporting by Akankshita Mukhopadhyay in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below